Targeting innate, acquired and bypass resistance—with the end goal of transforming lives

ORIC was established in 2014 with a bold vision of Overcoming Resistance In Cancer.

Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time.

Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including anti-hormonal therapy, chemotherapy and immunotherapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors.

ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.

Leadership Team

Our leadership team has advanced multiple oncology therapeutics from early-stage research to clinical trials, and ultimately to regulatory approval and commercialization at biopharmaceutical companies like Ignyta, Medivation, Aragon, Seragon, Synthorx and Genentech.

Jacob Chacko, MD
President, Chief Executive Officer and Board Member
Lori Friedman, PhD
Chief Scientific Officer
Pratik Multani, MD
Chief Medical Officer
Matthew Panuwat
Chief Business Officer
Dominic Piscitelli
Chief Financial Officer
Christian V. Kuhlen, MD, JD
General Counsel
Edna Chow Maneval, PhD
Senior Vice President, Clinical Development
Board of Directors

Our board has decades of experience founding and building leading oncology companies.

Richard Heyman, PhD
Chairman, Founder,
Scientific Advisory Board
Mardi C. Dier
EVP and CFO of Ultragenyx Pharmaceuticals
Carl L. Gordon, PhD, CFA
Board Member
Managing Partner, OrbiMed
Lori Kunkel, MD
Board Member
Richard Scheller, PhD
Board Member,
Scientific Advisory Board
Chairman of Research & Development, BridgeBio
Peter Svennilson
Board Member
Managing Partner, The Column Group
Jacob Chacko, MD
Board Member
President and Chief Executive Officer
Charles Sawyers, MD
Scientific Advisory Board
Professor, Memorial Sloan Kettering Cancer Center
Scott Lowe, PhD
Scientific Advisory Board
Professor, Memorial Sloan Kettering Cancer Center
Richard Heyman, PhD
Chairman, Founder,
Scientific Advisory Board

Corporate Headquarters
240 E. Grand Ave
2nd Floor
South San Francisco, CA 94080
San Diego Offices
12526 High Bluff Drive
Suite 360
San Diego, CA 92130